RESUMEN
Two new noncentrosymmetric polar gallium fluorophosphates have been synthesized under mild hydrothermal conditions through the use of enantiomorphically pure sources of either R-2-methylpiperazine or S-2-methylpiperazine. A centrosymmetric analogue was also prepared using a racemic source of the amine. Novel [Ga(3)F(PO(4))(4)](n)(4n-) layers, constructed from [Ga(3)O(3)F(PO(4))(4)] building units, are observed in all three compounds. The use of racemic 2-methylpiperazine results in crystallographic disorder of the amines and creation of inversion centers, while using a single enantiomer destroys the inversion symmetry and orders the amines. Second harmonic generation measurements were performed on [(R)-C(5)H(14)N(2)](2)[Ga(3)F(PO(4))(4)] x 5.5 H(2)O and [(S)-C(5)H(14)N(2)](2)[Ga(3)F(PO(4))(4)] x 4.75 H(2)O, both of which display type 1 phase-matching capabilities and exhibit activities of approximately 50 x alpha-SiO(2). The structures of these compounds were determined using single crystal X-ray diffraction, infrared spectroscopy, and thermal analyses. [C(5)H(14)N(2)](2)[Ga(3)F(PO(4))(4)] x 5.25 H(2)O, a = 13.0863(5) A, c = 9.9023(4) A, trigonal, P-3 (No. 147), Z = 2; [(R)-C(5)H(14)N(2)](2)[Ga(3)F(PO(4))(4)] x 5.5 H(2)O, a = 13.0887(2) A, c = 29.9439(4) A, trigonal, P3(1) (No. 144), Z = 6; [(S)-C(5)H(14)N(2)](2)[Ga(3)F(PO(4))(4)] x 4.75 H(2)O, a = 13.0871(2) A, c = 29.8350(6) A, trigonal, P3(2) (No. 145), Z = 6.
RESUMEN
Hepatocyte growth factor (HGF) is an important regulator of normal development and homeostasis, and dysregulated signaling through the HGF receptor, Met, contributes to tumorigenesis, tumor progression, and metastasis in numerous human malignancies. The development of selective small-molecule inhibitors of oncogenic tyrosine kinases (TK) has led to well-tolerated, targeted therapies for a growing number of cancer types. To identify selective Met TK inhibitors, we used a high-throughput virtual screen of the 13.5 million compound ChemNavigator database to find compounds most likely to bind to the Met ATP binding site and to form several critical interactions with binding site residues predicted to stabilize the kinase domain in its inactive conformation. Subsequent biological screening of 70 in silico hit structures using cell-free and intact cell assays identified three active compounds with micromolar IC(50) values. The predicted binding modes and target selectivity of these compounds are discussed and compared to other known Met TK inhibitors.
Asunto(s)
Antineoplásicos/química , Simulación por Computador , Descubrimiento de Drogas/métodos , Inhibidores de Proteínas Quinasas/química , Proteínas Proto-Oncogénicas/antagonistas & inhibidores , Receptores de Factores de Crecimiento/antagonistas & inhibidores , Antineoplásicos/farmacología , Sitios de Unión , Línea Celular Tumoral , Humanos , Concentración 50 Inhibidora , Unión Proteica , Inhibidores de Proteínas Quinasas/farmacología , Proteínas Proto-Oncogénicas c-metRESUMEN
Reported herein are the design, synthesis, and Grb2 SH2 domain-binding affinities of several phosphoryl-mimicking groups displayed within the context of a conformationally constrained macrocyclic platform. With use of surface plasmon resonance techniques, single-digit nanomolar affinities were exhibited by phosphonic acid and malonyl-containing diacidic phosphoryl mimetics (for 4h and 4g, K(D) = 1.47 and 3.62 nM, respectively). Analogues containing monoacidic phosphoryl mimetics provided affinities of K(D) = 16-67 nM. Neutral phosphoryl-mimicking groups did not show appreciable binding.